Chronic Kidney Disease Is Associated With Greater Bone Marrow Adiposity.
Chronic Kidney Disease Is Associated With Greater Bone Marrow Adiposity.
复制标题
DOI：
10.1002/jbmr.3562
复制
发表时间：
2018-12
期刊：
影响因子：
--
通讯作者：
Schwartz AV
中科院分区：
文献类型：
--
作者：
Woods GN;Ewing SK;Sigurdsson S;Kado DM;Ix JH;Hue TF;Eiriksdottir G;Xu K;Gudnason V;Lang TF;Vittinghoff E;Harris TB;Rosen CJ;Li X;Schwartz AV
骨髓肥胖症与衰老、骨质疏松症、造血功能减退以及神经性厌食症有关，但对影响骨髓肥胖症的潜在机制知之甚少。慢性肾脏疾病(CKD)可能会影响骨髓脂肪组织(BMAT)，可能是通过瘦质量丧失或循环中较高的硬化素水平。为了验证这些假设，我们从年龄基因/环境易感性(AGEs)-雷克雅未克研究中调查了475名老年人作为肾功能衡量指标的估计肾小球滤过率(EGFR)与基于1H-MRS的脊椎BMAT(L1至L4)测量之间的横截面关联。使用线性回归模型比较EGFR>；60(n=297)与EGFR 45-60(n=120)或EGFR<；45(n=58)患者的平均BMAT。受试者平均年龄81.5岁(SD 4.1)，平均EGFR为64.3(SD 16.1)毫升/分钟/1.734 cm~2，平均BMAT为54.5%(SD 8.5)，其中48.2%为女性。在未调整和调整的模型(年龄、就诊窗口、性别、糖尿病和内脏脂肪组织)中，与EGFR和GT；60(调整后平均53.8%；95%可信区间，52.8%至54.8%)相比，EGFR+lt；45(调整后平均值为58.5%；95%CI，56.2%至60.7%)患者的BMAT更高(p=0.0002)。与EGFR和GT；60的患者相比，EGFR为45~60的患者的BMAT差异无统计学意义(调整后平均值为54.3%；95%可信区间为52.8至55.9)。在一组血清硬化素可用的受试者(n=253)中，对硬化素的额外调整使那些患有EGFR；lt；45和>；60的患者调整后的平均椎体BMAT的差异从3.7%(p=0.04)减小到2.4%(p=0.20)。CKD分期3b或更差与更大的骨髓肥胖症相关；这种关联可能部分由硬化素介导。2018年美国骨与矿物研究学会。
Bone marrow adiposity is associated with aging, osteoporosis, and reduced hematopoiesis, as well as anorexia nervosa, but little is known about the underlying mechanisms that affect marrow adiposity. Chronic kidney disease (CKD) may influence bone marrow adipose tissue (BMAT), possibly through loss of lean mass or higher circulating levels of sclerostin. To test these hypotheses, we investigated the cross-sectional association between estimated glomerular filtration rate (eGFR) as a measure of kidney function and 1H-MRS-based measurement of vertebral BMAT (L1 to L4) in 475 older adults from the Age Gene/Environment Susceptibility (AGES)-Reykjavik study. Mean BMAT was compared in those with eGFR >60 (n = 297) versus those with eGFR 45 to 60 (n = 120) or eGFR <45 (n = 58) using linear regression models. Participants had a mean age of 81.5 (SD 4.1) years, mean eGFR of 64.3 (SD 16.1) mL/min/1.734 cm2, mean BMAT of 54.5% (SD 8.5); 48.2% were women. In unadjusted and adjusted models (age, visit window, gender, diabetes and visceral adipose tissue), BMAT was higher in those with eGFR <45 (adjusted mean 58.5%; 95% CI, 56.2 to 60.7) compared with those with eGFR >60 (adjusted mean 53.8%; 95% CI, 52.8 to 54.8) (p = 0.0002). BMAT did not differ in those with eGFR 45 to 60 (adjusted mean 54.3%; 95% CI, 52.8 to 55.9) compared with those with eGFR >60 (p = 0.58). In a subgroup of participants with serum sclerostin available (n = 253), additional adjustment for sclerostin attenuated the difference in adjusted mean vertebral BMAT between those with eGFR <45 versus >60 from 3.7% (p = 0.04) to 2.4% (p = 0.20). CKD stage 3b or worse was associated with greater bone marrow adiposity; this association may be partially mediated by sclerostin. © 2018 American Society for Bone and Mineral Research.
登录
查看更多内容
影响因子：
5.2
作者：
Tencerova M;Kassem M
通讯作者：
Kassem M
影响因子：
6.2
作者：
Qiu, Weimin;Andersen, Tom E.;Kassem, Moustapha
通讯作者：
Kassem, Moustapha
影响因子：
5.8
作者：
McNulty, Melissa;Singh, Ravinder J.;Kumar, Rajiv
通讯作者：
Kumar, Rajiv
影响因子：
5.2
作者：
Schwartz AV
通讯作者：
Schwartz AV
DOI：
10.2215/cjn.07670712
发表时间：
2013-05-01
影响因子：
9.8
作者：
Pelletier, Solenne;Dubourg, Laurence;Fouque, Denis
通讯作者：
Fouque, Denis